ClinicalTrials.gg
CompletedNCT03414268Updated May 19, 2022

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

A Phase 3 interventional study of Micronized dHACM and Saline Injection in Fasciitis, Plantar, sponsored by MiMedx Group, Inc.. Completed at 17 sites in United States. Open to participants aged 21 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by MiMedx Group, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.
Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
21 Years to 79 Years
Sex
All
01

Study summary

Prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis

Read the detailed description

Approximately 276 patients will be enrolled in this study. Each patient will receive 1 injection and be evaluated for efficacy and safety during a 6-month observation period. Randomization will be 1:1. The study is expected to be completed within 34 months, inclusive of enrollment and follow-up of all subjects.

02

Conditions studied

  • Fasciitis, Plantar

Browse trials for

Keywords

  • Chronic plantar fasciitis
  • Heel pain
03

In context

Fasciitis, Plantar

223 studies on the registry are indexed under Fasciitis, Plantar; 58 are open to participants now.

This study's enrollment of 208 is above the median of 56 across 194 interventional studies indexed under Fasciitis, Plantar.

Browse Fasciitis, Plantar studies →

Lead sponsor

MiMedx Group, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of plantar fasciitis for ≥ 1 month (30 days) and ≤ 18 months by the investigator
  2. VAS Pain scale of ≥ 45 mm at randomization
  3. Plantar fasciitis with conservative treatment for ≥ 1 month (30 days), including any of the following modalities:

    • RICE
    • Stretching exercises
    • NSAIDs
    • Orthotics
  4. Diagnostic X-Ray within 6 months of enrollment showing view of calcaneus negative for calcaneal fracture or structural abnormalities
  5. ≤ 40 kg/m2
  6. Age ≥ 21 years and \< 80 years
  7. Ability to sign and Release of Medical Information Forms
  8. Ability to receive and respond to text messages or emails on a daily basis.

Exclusion criteria

Exclusion Criteria:

  1. Prior surgery or trauma to the affected site
  2. Subjects requiring bilateral plantar fasciitis treatment at time of enrollment
  3. Prior use of any lower limb injection therapy, including or PRP in either limb within the last 3 months
  4. Has diabetes either Type I or Type II.
  5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.
  6. The presence of diagnosed comorbidities that can be confused with or can exacerbate the condition- to be assessed by X-ray - including but not limited to:

    • Calcaneal stress fracture
    • Nerve entrapment syndrome (diagnosed as Baxter Nerve Syndrome)
    • Fat pad atrophy
    • Acute traumatic rupture of the plantar fascia
    • Calcaneal tumor
    • Tarsal tunnel syndrome (diagnosed)
    • Significant bone deformity of the foot that may interfere with the study
  7. Affected site exhibits clinical signs and symptoms of infection
  8. Known allergy or known sensitivity to Aminoglycosides
  9. Subjects who are non-ambulatory
  10. History of more than 14 days treatment with immuno-suppressants (including systemic corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who are anticipated to require such medications during the course of the study
  11. Prior radiation at the site
  12. Use of any drug(s) or therapeutic device(s) within 3 months preceding enrollment
  13. Immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or (HIV)
  14. History of any condition (including drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol, in the judgment of the investigator
  15. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of (birth control pills, barriers, or abstinence)
  16. Workers' compensation subjects
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Micronized dHACM

    1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)

    Other: Micronized dHACM

  • Placebo comparator
    Saline Injection

    Injection of 1mL 0.9% Sodium Chloride Injection, USP

    Drug: Saline Injection

Interventions

  • OtherMicronized dHACM

    1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)

    Also known as: dHACM

  • DrugSaline Injection

    Injection of 1mL 0.9% Sodium Chloride Injection, USP

    Also known as: 0.9% NaCl, Normal Saline, Sodium Chloride Injection, USP

06

What researchers measure

Primary outcomes

  1. Change in VAS score

    Visual Analog Scale for Pain:

    Time frame: 90 Days

  2. Incidence of adverse events

    The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events during the first 12 months post injection

    Time frame: 180 Days

Secondary outcomes

  1. Foot Function Index - Revised (FFI-R) (Short Form)

    Foot Function Index - Revised: Patient Reported Questionnaire

    Time frame: 90 Days

07

Study locations

17 sites
  • Southern Arizona VA Health Care System
    Tucson, Arizona 85723, United States
  • ILD Research Center
    Carlsbad, California 92009, United States
  • Center for Clinical Research
    Carmichael, California 95608, United States
  • Limb Preservation Platform, Inc.
    Fresno, California 93721, United States
  • Horizon Clinical Research
    La Mesa, California 91942, United States
  • Foot and Ankle Clinic
    Los Angeles, California 90057, United States
  • Five Cities Foot Clinic
    Pismo Beach, California 93449, United States
  • Bay Pines VA Healthcare System
    Bay Pines, Florida 33744, United States
  • Gulfcoast Research Institute, LLC
    Sarasota, Florida 34232, United States
  • Doctors Research Network
    South Miami, Florida 33143, United States
  • Union Podiatry
    Baltimore, Maryland 21218, United States
  • Advanced Foot & Ankle Center
    Las Vegas, Nevada 89119, United States
  • University Orthopedics Center
    Altoona, Pennsylvania 16602, United States
  • University Orthopedics Center
    State College, Pennsylvania 16801, United States
  • Futuro Clinical Trials, LLC
    McAllen, Texas 78501, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
  • Coastal Podiatry
    Virginia Beach, Virginia 23464, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Mar 2021, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2018
First posted
Jan 29, 2018
StartActual
Jan 8, 2018
Primary completionActual
Mar 17, 2021
CompletionActual
Mar 17, 2021
Last update
May 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03414268
Lead sponsor
MiMedx Group, Inc.
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
Jan 8, 2018
Primary completion
Mar 17, 2021
Completion
Mar 17, 2021
Last update
May 19, 2022

Study contacts

Stuart D Miller, MD
principal investigator · MedStar Union Memorial Hospital, Baltimore, MD

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion